Cardiac Dimensions names new vice president of R&D
Mr Conta comes to Cardiac Dimensions from Spiration, a medical device company. Prior to Spiration, he ran R&D operations for Spinal Dynamics, Wright Medical Technology, Joint Medical Products
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
Cenix will apply InteRNA’s lentiviral-based miRNA overexpression library in high throughput screening assays in combination with high content, multi-parametric phenotypic analyses to identify the biological role of individual